Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CRYSTAL D FAUDERE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1083685291
CMS profile
820957
Location
EL DORADO, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,456.60

128 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,456.60 128

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CRYSTAL D FAUDERE

NPI 1083685291 · CMS profile ID 820957

Allopathic & Osteopathic Physicians / Family Medicine

EL DORADO, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083685291?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CRYSTAL D FAUDERE, NPI 1083685291, CMS profile ID 820957. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083685291?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CRYSTAL D FAUDERE, NPI 1083685291, CMS profile ID 820957. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083685291?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CRYSTAL D FAUDERE, NPI 1083685291, CMS profile ID 820957, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1083685291?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

128 matching records · $2,456.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 128 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–128 of 128.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $12.3503/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227062439 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.3703/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222955832 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.9903/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231848011 CMS
PFIZER INC. $20.6803/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231548397 CMS
Lilly USA, LLC $16.6003/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186622330 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.6803/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225533646 CMS
AstraZeneca Pharmaceuticals LP $19.1903/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206963495 CMS
Novo Nordisk Inc $18.1503/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188384338 CMS
GlaxoSmithKline, LLC. $15.0203/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190359587 CMS
PFIZER INC. $17.6303/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231635374 CMS
Otsuka America Pharmaceutical, Inc. $10.1702/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227326128 CMS
Astellas Pharma US Inc $18.9202/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238603322 CMS
Novo Nordisk Inc $14.9602/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188304644 CMS
Otsuka America Pharmaceutical, Inc. $15.2202/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227326126 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.7502/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225533644 CMS
Merck Sharp & Dohme LLC $14.5302/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238050633 CMS
PFIZER INC. $14.6902/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231332939 CMS
Amgen Inc. $20.3401/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228444527 CMS
Astellas Pharma US Inc $17.5701/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238722384 CMS
ABBVIE INC. $10.6301/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201842697 CMS
PFIZER INC. $19.8401/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231114982 CMS
Otsuka America Pharmaceutical, Inc. $15.3001/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227326124 CMS
ABBVIE INC. $5.2201/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201842695 CMS
IDORSIA PHARMACEUTICALS US INC $16.9601/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243395121 CMS
AstraZeneca Pharmaceuticals LP $145.9701/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206887167 CMS
Novo Nordisk Inc $1.7201/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188401866 CMS
Novo Nordisk Inc $13.5401/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189004145 CMS
PFIZER INC. $9.2601/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231235443 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $411.40 31
PY2020 $1,221.39 86
PY2021 $2,174.07 148
PY2022 $2,598.93 175
PY2023 $3,386.22 135
PY2024 $2,297.11 127
PY2025 $2,456.60 128

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $174.08 6
PY2025 Principal investigator $318,377.76 132
PY2024 Recipient $4,337.57 31
PY2024 Principal investigator $445,897.67 23
PY2023 Principal investigator $258,485.63 18
PY2022 Principal investigator $359,332.62 22
PY2021 Principal investigator $132,599.89 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

138 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 12/17/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726461
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 12/17/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726463
Principal investigator 1 Boehringer Ingelheim International GmbH $34.80 12/17/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726465
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,231.92 12/15/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798791
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $673.00 12/15/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798793
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726449
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726451
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726453
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726455
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726457
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726459
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726435
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726437
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726439
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726441
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726443
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726445
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726447
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,088.62 10/29/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798789
Principal investigator 1 AstraZeneca Pharmaceuticals LP $55,393.24 10/08/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185548293
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726423
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726425
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726427
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726429
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726431
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726433
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,664.70 10/01/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798783
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $905.00 10/01/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798785
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 10/01/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798787
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $218.85 10/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808046
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726419
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 09/24/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726421
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808044
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,657.82 09/18/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798781
Principal investigator 1 GlaxoSmithKline, LLC. $3,500.00 09/10/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192110951
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 09/10/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192110962
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726385
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726387
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726389
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726391
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726393
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726411
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 09/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726413
Principal investigator 1 GlaxoSmithKline, LLC. $1,044.00 08/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192110967
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27,218.52 08/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798779
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726375
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726377
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726379
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726381
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726383
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726405
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726409
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,194.30 07/31/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798777
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726415
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 07/28/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726417
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726395
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726397
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726399
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726401
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726403
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726407
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,799.44 06/26/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798775
Principal investigator 1 Boehringer Ingelheim International GmbH $84.00 06/24/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726365
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 06/24/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726367
Principal investigator 1 Boehringer Ingelheim International GmbH $876.00 06/24/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726369
Principal investigator 1 Boehringer Ingelheim International GmbH $29.58 06/24/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726371
Principal investigator 1 Boehringer Ingelheim International GmbH $24.84 06/24/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726373
Principal investigator 1 GlaxoSmithKline, LLC. $14,550.00 06/13/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192110945
Principal investigator 1 GlaxoSmithKline, LLC. $450.00 06/13/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192110956
Principal investigator 1 GlaxoSmithKline, LLC. $3,169.40 06/11/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1192110973
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726345
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726347
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726349
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726351
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726353
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726355
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 05/27/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726361
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 05/27/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726363
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,972.30 05/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798773
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,927.22 05/09/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798771
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726331
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726333
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726335
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726337
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726339
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726341
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726343
Principal investigator 1 SANOFI PASTEUR INC. $500.00 04/28/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226113804
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 04/23/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726357
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 04/23/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726359
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,127.90 04/11/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798769
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726319
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726321
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726323
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726325
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726327
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726329
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 03/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726311
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 03/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726313
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 03/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726315
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $35,086.94 03/25/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798767
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726279
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726281
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726283
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726285
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726287
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726289
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 02/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726299
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 02/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726301
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726303
Principal investigator 1 Boehringer Ingelheim International GmbH $1,105.50 02/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726305
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 02/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726307
Principal investigator 1 Boehringer Ingelheim International GmbH $27.60 02/25/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726309
Recipient GlaxoSmithKline, LLC. $60.00 02/07/2025 Covered Recipient Physician A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192117406
Recipient GlaxoSmithKline, LLC. $36.29 02/07/2025 Covered Recipient Physician A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192117412
Recipient GlaxoSmithKline, LLC. $5.84 02/07/2025 Covered Recipient Physician A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192117418
Recipient GlaxoSmithKline, LLC. $14.57 02/07/2025 Covered Recipient Physician A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192117426
Recipient GlaxoSmithKline, LLC. $3.78 02/07/2025 Covered Recipient Physician A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192117432
Recipient GlaxoSmithKline, LLC. $53.60 02/07/2025 Covered Recipient Physician A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192117442
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726267
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726269
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726271
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726273
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726275
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726277
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 01/27/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726291
Principal investigator 1 Boehringer Ingelheim International GmbH $2.17 01/27/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726293
Principal investigator 1 Boehringer Ingelheim International GmbH $2.03 01/27/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726295
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 01/27/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726297
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $964.00 01/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798763
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,498.62 01/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798765
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,074.76 01/17/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798761
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726257
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726259
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726261
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726263
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726265
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Amr El Dorado
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726317